Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be of Asian descent.~* Screening laboratory result indicating hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5 or 6 infection.~* Positive anti-HCV antibody (Ab) and HCV ribonucleic acid (RNA) greater than or equal to 1000 IU/ mL at Screening Visit.~* Chronic HCV infection defined as one of the following:~  * Positive for anti-HCV Ab or HCV RNA at least 6 months before Screening; or~ * A liver biopsy consistent with chronic HCV infection;~* HCV treatment-naïve to any approved or investigational HCV treatment or treatment-experienced with interferon (IFN) (alpha, beta or pegylated interferon \[pegIFN\] with or without ribavirin (RBV) OR sofosbuvir with RBV with or without IFN. Previous treatment must have been completed \>= 8 weeks prior to screening.~* Compensated cirrhosis defined as Child-Pugh score of ≤ 6 at Screening and no current or past clinical evidence of Child-Pugh B or C Classification or clinical history of liver decompensation including ascites noted on physical exam, bleeding varices, use of diuretics for ascites, or hepatic encephalopathy.~* Absence of hepatocellular carcinoma (HCC)~Participants enrolled with human immunodeficiency virus (HIV)-1 and HCV co-infection must also meet the following criteria:~* Positive test result for human immunodeficiency virus antibody (HIV Ab) at Screening.~* Naïve to treatment with any antiretroviral therapy (ART) with a cluster of differentiation (CD)4+ count greater than or equal to 500 cells/mm³ (or CD4+ % \>= 29%), or~* On a stable, qualifying HIV-1 ART regimen with CD4+ count \>= 200 cells/mm³ (or CD4+ % \>= 14%) at Screening; and plasma HIV-1 RNA below lower limit of quantification (LLOQ) by an approved plasma HIV-1 RNA quantitative assay at Screening and at least once during the 12 months prior to Screening.~Exclusion Criteria:~* Positive test result for hepatitis B surface antigen (HbsAg) or positive test result for hepatitis B virus (HBV) deoxyribonucleic acid (DNA) if HBsAg is negative.~* Any cause of liver disease other than chronic HCV-infection.~* HCV genotype performed during screening indicating co-infection with more than one HCV genotype~* Clinically significant abnormalities, other than HCV infection or HCV/HIV co-infection~* Chronic human immunodeficiency virus, type 2 (HIV-2) infection~Additional Exclusion Criteria for participants with HCV/HIV Co-Infection:~* For participants on stable ART, taking anti-retroviral agent(s) other than those permitted~* Treatment for an acquired immunodeficiency syndrome (AIDS)-associated opportunistic infection within 12 months of Screening or prophylaxis for an AIDS-associated opportunistic infection within 6 months of screening~* Diagnosis of any clinical AIDS-defining event within 12 months prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glecaprevir/Pibrentasvir (Type: EXPERIMENTAL): Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).